{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:13:58Z","timestamp":1790284438457,"version":"4.1.0"},"reference-count":37,"publisher":"RCNi","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.7748\/ns.2025.e12403","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:00:06Z","timestamp":1744614006000},"page":"54-59","source":"Crossref","is-referenced-by-count":1,"title":["Developments in the treatment of multiple myeloma: overview and nursing implications"],"prefix":"10.7748","volume":"40","author":[{"given":"Samantha","family":"Toland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4499","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"10","key":"key20250603120130_R1","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers12102885","article-title":"Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020","volume":"12","year":"2020","journal-title":"Cancers"},{"key":"key20250603120130_R2","unstructured":"Cancer Research UK (2025) Myeloma Statistics: Myeloma Survival. www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma#heading-Two (Last accessed: 18 March 2025.)"},{"issue":"7","key":"key20250603120130_R3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/cancers15071929","article-title":"30 years of improved survival in non-transplant-eligible newly diagnosed multiple myeloma","volume":"15","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"key20250603120130_R4","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","year":"2019","journal-title":"Lancet Haematology"},{"issue":"2","key":"key20250603120130_R5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.12968\/bjon.2020.29.2.103","article-title":"Patients\u2019 experiences of living with multiple myeloma","volume":"29","year":"2020","journal-title":"British Journal of Nursing"},{"issue":"5","key":"key20250603120130_R6","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","year":"2017","journal-title":"Haematologica"},{"issue":"9594","key":"key20250603120130_R7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"key20250603120130_R8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/BLCTT.S91251","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","year":"2016","journal-title":"Blood and Lymphatic Cancer: Targets and Therapy"},{"issue":"22","key":"key20250603120130_R9","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"key20250603120130_R10","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.12968\/bjon.2023.32.5.S10","article-title":"A survey of quality-of-life tools used in the routine care of patients with multiple myeloma","volume":"32","year":"2023","journal-title":"British Journal of Nursing"},{"issue":"2","key":"key20250603120130_R11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1188\/21.ONF.151-160","article-title":"A qualitative study of the experiences of living with multiple myeloma","volume":"48","year":"2021","journal-title":"Oncology Nursing Forum"},{"key":"key20250603120130_R12","unstructured":"Macmillan Cancer Support (2025) Holistic Needs Assessments. www.macmillan.org.uk\/healthcare-professionals\/innovation-in-cancer-care\/holistic-needs-assessment (Last accessed: 17 March 2025.)"},{"issue":"11","key":"key20250603120130_R13","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"key20250603120130_R14","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","year":"2020","journal-title":"Lancet Haematology"},{"issue":"13","key":"key20250603120130_R15","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"key20250603120130_R16","volume-title":"Introducing Pharmacology for Nursing and Healthcare","year":"2019","edition":"3"},{"key":"key20250603120130_R17","unstructured":"MCT Myeloma Clinical Trials (2022) What are Multiple Myeloma Defining Events? International Myeloma Working Group \u2013 SLiM-CRAB Criteria. www.themyelomaclinicaltrials.com\/single-post\/slim-crabcriteria (Last accessed: 18 March 2025.)"},{"issue":"17","key":"key20250603120130_R18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2023.32.17.S4","article-title":"Advances in the management of myeloma: an update","volume":"32","year":"2023","journal-title":"British Journal of Nursing"},{"issue":"2","key":"key20250603120130_R19","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2020.09.010","article-title":"Burden of treatment among older adults with newly diagnosed multiple myeloma","volume":"21","year":"2021","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"key20250603120130_R20","unstructured":"Myeloma UK (2025a) Symptoms and Complications. www.myeloma.org.uk\/understanding-myeloma\/symptoms-and-complications-of-myeloma (Last accessed: 17 March 2025.)"},{"key":"key20250603120130_R21","unstructured":"Myeloma UK (2025b) Belantamab Mafodotin (Blenrep\u00ae): Horizons Infosheet: Clinical Trials and New Treatments. www.myeloma.org.uk\/wp-content\/uploads\/2025\/03\/Myeloma-UK-Belantamab-Mafodotin-Horizons-Infosheet.pdf (Last accessed: 18 March 2025.)"},{"key":"key20250603120130_R22","volume-title":"Technology appraisal No. 695","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key20250603120130_R23","volume-title":"Technology appraisal No. 783","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key20250603120130_R24","volume-title":"Technology appraisal No. 917","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key20250603120130_R25","volume-title":"Technology appraisal No. 897","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key20250603120130_R26","volume-title":"Technology appraisal No. 870","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key20250603120130_R27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12885-015-1261-6","article-title":"Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)","volume":"15","year":"2015","journal-title":"BMC Cancer"},{"issue":"13","key":"key20250603120130_R28","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","year":"2015","journal-title":"Blood"},{"issue":"14","key":"key20250603120130_R29","first-page":"253","article-title":"Patients with multiple myeloma or monoclonal gammopathy of undetermined significance: diagnosis, treatment, and follow-up","volume":"119","year":"2022","journal-title":"Deutsches A\u00a8rzteblatt International"},{"issue":"20","key":"key20250603120130_R30","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"key20250603120130_R31","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","year":"2014","journal-title":"Lancet Oncology"},{"issue":"8","key":"key20250603120130_R32","doi-asserted-by":"crossref","first-page":"e0201699","DOI":"10.1371\/journal.pone.0201699","article-title":"The need for information among patients with hematological malignancies: psychometric analyses of the 62-item Hematology Information Needs Questionnaire (HINQ-62)","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"key20250603120130_R33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","year":"2017","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"2","key":"key20250603120130_R34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","year":"2021","journal-title":"British Journal of Haematology"},{"issue":"6","key":"key20250603120130_R35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","year":"2017","journal-title":"British Journal of Haematology"},{"key":"key20250603120130_R36","unstructured":"U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (Last accessed: 18 March 2025.)"},{"issue":"4","key":"key20250603120130_R37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ibra.12132","article-title":"Recent advances in the treatment and prevention of peripheral neuropathy after multiple myeloma treatment","volume":"9","year":"2023","journal-title":"Ibrain"}],"container-title":["Nursing Standard"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.rcni.com\/doi\/pdf\/10.7748\/ns.2025.e12403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:10:29Z","timestamp":1749021029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.rcni.com\/doi\/10.7748\/ns.2025.e12403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,14]]},"published-print":{"date-parts":[[2025,6,4]]}},"alternative-id":["10.7748\/ns.2025.e12403"],"URL":"https:\/\/doi.org\/10.7748\/ns.2025.e12403","relation":{},"ISSN":["0029-6570","2047-9018"],"issn-type":[{"value":"0029-6570","type":"print"},{"value":"2047-9018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}